BioSpace News Archive

The report, PARP (poly ADP-ribose polymerase) inhibitors market 2019-2023, has been added to Technavio’s catalog.

The report, permanent artificial skin market 2019-2023, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on end-user and geography for the forecast period 2019-2023.

Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice

The report, spasticity treatment market 2019-2023, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type and geography for the forecast period 2019-2023.

ESSA Pharma Inc. (“ESSA” or the “Company”) (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the “Board”) pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences.

The U.S. Food and Drug Administration is alerting consumers of a voluntary recall by Johnson & Johnson of Johnson’s Baby Powder after FDA testing has found that a sample from one lot of the product contains chrysotile fibers, a type of asbestos.

Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced the company will participate in the upcoming Recent Advances in Fermentation Technology Conference to be held October 29 - November 1, 2017 at the Hyatt Coconut Point, Bonita Springs, Florida.

Oxford-based start-up Ultromics has announced the appointment of Amir Hasan as Chief Commercial Officer

IRRAS announced that it will be participating at the 69th Congress of Neurological Surgeons’ Annual Meeting CNS 2019 is being held at the Moscone Center, West Building, in San Francisco, CA on October 19-23, 2019.

NGM Biopharmaceuticals, Inc. announced that it will present at two upcoming conferences focused on drug research and development for non-alcoholic steatohepatitis NGM’s lead clinical candidate, aldafermin, is currently in Phase 2b clinical development for the treatment of NASH.